ReviewVirology journal2025
Endothelial leak and knowledge gaps: yellow fever virus non-structural protein 1 and the antibodies that bind it.
Review in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Yellow fever virus, family Orthoflaviviridae, is the causative agent of yellow fever - a lethal mosquito-borne disease endemic to South America and Africa. Recent advances in understanding the mechanism of orthoflavivirus pathogenesis, particularly for dengue (DENV), demonstrate a role for the secreted viral non-structural protein 1 (NS1) in both animal and human models. The NS1 protein's most well described pathogenic mechanism is its ability to induce vascular endothelial permeability in a tissue organ specific manner, contributing to orthoflavivirus disease severity. Surprisingly, there is minimal research published on the role of NS1 in YFV pathogenesis, despite the clear and present danger of YFV outbreaks in endemic countries. Understanding the role of NS1 in YFV pathogenesis is critical for the development of therapeutic interventions. Notably, while vaccination efforts for orthoflaviviruses have been historically difficult, the live attenuated vaccine (YFV-17D) against YFV has been hailed as not only the most successful orthoflavivirus vaccine but is among the most successful live virus vaccines ever created. Despite YFV-17D's widespread use since its introduction in the 1930's, the best described mechanism of protection is the vaccine's potent neutralizing antibodies. Our knowledge of NS1 pathogenic mechanisms has expanded since the development of YFV-17D, but how vaccine mediated immunity may interact with NS1 during natural YFV infection is not well described. In this review we describe the current knowledge of YFV NS1 mediated pathogenesis and adaptive immunity directed against YFV NS1 in a variety of animal and human models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.